KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Total Non-Current Liabilities (2016 - 2026)

Palvella Therapeutics has reported Total Non-Current Liabilities over the past 10 years, most recently at $67.6 million for Q4 2022.

  • Quarterly Total Non-Current Liabilities fell 34.28% to $67.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $67.6 million through Dec 2022, down 34.28% year-over-year, with the annual reading at $67.6 million for FY2022, 34.28% down from the prior year.
  • Total Non-Current Liabilities was $67.6 million for Q4 2022 at Palvella Therapeutics, down from $102.8 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $122.5 million in Q1 2018 and troughed at $67.6 million in Q4 2022.
  • The 5-year median for Total Non-Current Liabilities is $101.1 million (2018), against an average of $96.2 million.
  • Year-over-year, Total Non-Current Liabilities skyrocketed 179.72% in 2018 and then crashed 34.28% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $101.4 million in 2018, then decreased by 11.48% to $89.7 million in 2019, then dropped by 17.57% to $74.0 million in 2020, then soared by 38.97% to $102.8 million in 2021, then crashed by 34.28% to $67.6 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Total Non-Current Liabilities are $67.6 million (Q4 2022), $102.8 million (Q4 2021), and $110.3 million (Q3 2021).